The general objective of the VAGABOND project is to create a multidisciplinary and multisectoral program aimed at extending the technical-scientific knowledge of young researchers with the final aim of developing an efficient approach for the validation of new combinations of target-specific drugs in pediatric cancers.
In Europe, 25% of children diagnosed with cancer die from a relapse of the disease, usually after intensive treatment. And of the children who are recovered, more than 70% experience serious late effects, ranging from psychological problems to heart failure and secondary cancers. This demonstrates the clinical need for the development of new targeted drugs that are less toxic and more effective for improving quality of life.
The general objective of the VAGABOND project is to create a multidisciplinary and multisectoral program aimed at extending the technical-scientific knowledge of young researchers with the final aim of developing an efficient approach for the validation of new combinations of target-specific drugs in pediatric cancers. In particular, issues related to the study of the epigenetic characteristics of these tumors and to the typing of the immune microenvironment will be addressed.
The Laboratory of Experimental Oncology hosts a young European researcher, recruited under the "MSCA-ITN-2020-Innovative training network" programme.
Project: VAGABOND - Validation of Actionable Genomic ABerrations in a paediatric for Doctorate students
Acronymo: VAGABOND
Funding Program: Innovative Training Networks (ITN)
Tender notice: H2020-MSCA-ITN-2020
Topic: MSCA-ITN-2020-Innovative training networkCall: H2020-MSCA-ITN-2020
Duration: 01/12/2020-30/11/2024
Coordinator: Prinses Máxima Centrum voor Kinderoncologie B.V. (PMC)
Coordinator Scientific IOR: Katia Scotlandi
Budget IOR: 212.699,68 €
